Phase II trial of vinblastine in previously treated patients with ovarian cancer: a Southwest Oncology Group Study

• Published in: Gynecologic oncology Vol. 28; no. 1; p. 14
• Main Authors: Surwit, E A, Alberts, D S, O'Toole, R V, Graham, V, Hannigan, E V, Stephens, R L, Boutselis, J G
• Format: Journal Article
• Language: English
• Published: United States 01-09-1987
• Subjects: Adult; Aged; Carcinoma - drug therapy; Carcinoma - mortality; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Infusions, Intravenous; Leukopenia - chemically induced; Middle Aged; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - mortality; Thrombocytopenia - chemically induced; Time Factors; Vinblastine - administration & dosage; Vinblastine - adverse effects
• ISSN: 0090-8258
• DOI: 10.1016/S0090-8258(87)80003-3

Sixty-eight patients with relapsing, epithelial type ovarian carcinoma were entered into a Phase II study of vinblastine. Vinblastine was administered as a continuous intravenous infusion over 5 days at a starting dose of 1.7 mg/m2/day every 3 weeks. There were 44 fully evaluable and 6 partially evaluable patients. Forty-one of these patients had had only one prior treatment regimen. Grade 3 or 4 leukopenia occurred in 12 patients (24%), but Grade 3 or 4 thrombocytopenia occurred in only 2 patients. There were two clinical complete responses of 18- and 36-week durations and one partial response of 6 weeks for an overall response rate of 7%. We conclude that vinblastine, administered in optimal dose and schedule, has little clinical activity in previously treated patients with ovarian cancer.